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ORIGINAL ARTICLE
Impact of Fractional Flow Reserve Derived From 
Coronary Computed Tomography Angiography on 
Heart Team Treatment Decision-Making in Patients 
With Multivessel Coronary Artery Disease
Insights From the SYNTAX III Revolution Trial
Daniele Andreini, MD; et al
BACKGROUND: Fractional flow reserve (FFR) is a reliable tool for the functional assessment of coronary stenoses. FFR computed 
tomography (CT) derived (FFRCT) has shown to be accurate, but its clinical usefulness in patients with complex coronary artery 
disease remains to be investigated. The present study sought to determine the impact of FFRCT on heart team’s treatment 
decision-making and selection of vessels for revascularization in patients with 3-vessel coronary artery disease.
METHODS: The trial was an international, multicenter study randomizing 2 heart teams to make a treatment decision between 
percutaneous coronary interventions and coronary artery bypass grafting using either coronary computed tomography 
angiography or conventional angiography. The heart teams received the FFRCT and had to make a treatment decision and 
planning integrating the functional component of the stenoses. Each heart team calculated the anatomic SYNTAX score, the 
noninvasive functional SYNTAX score and subsequently integrated the clinical information to compute the SYNTAX score 
III providing a treatment recommendation, that is, coronary artery bypass grafting, percutaneous coronary intervention, or 
equipoise coronary artery bypass grafting-percutaneous coronary intervention. The primary objective was to determine the 
proportion of patients in whom FFRCT changed the treatment decision and planning.
RESULTS: Overall, 223 patients were included. Coronary computed tomography angiography assessment was feasible in 
99% of the patients and FFRCT analysis in 88%. FFRCT was available for 1030 lesions (mean FFRCT value 0.64±13). A 
treatment recommendation of coronary artery bypass grafting was made in 24% of the patients with coronary computed 
tomography angiography with FFRCT. The addition of FFRCT changed the treatment decision in 7% of the patients and 
modified selection of vessels for revascularization in 12%. With conventional angiography as reference, FFRCT assessment 
resulted in reclassification of 14% of patients from intermediate and high to low SYNTAX score tertile.
CONCLUSIONS: In patients with 3-vessel coronary artery disease, a noninvasive physiology assessment using FFRCT changed 
heart team’s treatment decision-making and procedural planning in one-fifth of the patients.
VISUAL OVERVIEW: A visual overview is available for this article.
CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02813473.
Key Words: angiography ◼ coronary artery disease ◼ coronary computed tomography angiography ◼ decision-making  
◼ percutaneous coronary intervention
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Revascularization by either percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG) is indicated in flow-limiting coronary 
stenoses to reduce myocardial ischemia and its adverse 
clinical manifestations.1 In patients with multivessel coro-
nary artery disease (CAD), physiology-guided coronary 
revascularization has shown to improve clinical outcomes 
compared with an angiographic assessment alone.2 
Determination of pressure-wire indexes such as fractional 
flow reserve (FFR) or instantaneous wave-free ratio has 
demonstrated that almost half of the lesions with a diam-
eter stenosis >50% are not hemodynamically significant.3
FFR derived from computed tomography angiog-
raphy (FFRCT) is a noninvasive method able to identify 
lesion-specific ischemia. In patients with multivessel 
disease, FFRCT has shown to have good diagnostic per-
formance with invasive pressure-wire assessment as 
reference.4 Moreover, the extent, severity, and functional 
component of CAD can be objectively quantified using 
the functional SYNTAX score.4 The functional SYNTAX 
score has higher discrimination for clinical events com-
pared with the anatomic SYNTAX score, while reducing 
inter-observer variability. The calculation of the SYNTAX 
score III, combining in a noninvasive setting anatomy, 
physiology and patient’s clinical information provides the 
heart team with individualized risk stratification and treat-
ment recommendation based on the predicted 4-year 
mortality in patients undergoing PCI or CABG.5
The SYNTAX III Revolution trial showed that in patients 
with left main or 3-vessel CAD treatment decision-mak-
ing based on coronary computed tomography angiogra-
phy (CTA) is in high agreement with the decision derived 
from conventional angiography.6 However, the influence 
of FFRCT on treatment decision-making and selection of 
vessels for revascularization remains to be investigated. 
Thus, the present study sought to determine the impact 
of FFRCT on heart team’s treatment decision and proce-
dural planning in patients with left main or 3-vessel CAD.
METHODS
The data that support the findings of this study are available 
from the corresponding author on reasonable request.
Study Design
The present study reports the secondary end point of the 
SYNTAX III REVOLUTION trial. The design of the SYNTAX III 
REVOLUTION Trial, a randomized study investigating the use 
of CT scan and angiography of the heart to help the doctors 
decide which method is the best to improve blood supply to 
the heart in patients with complex coronary artery disease, has 
been reported previously.5 The trial was an international, multi-
center study randomizing 2 heart teams to make a treatment 
decision between PCI and CABG using either coronary CTA or 
conventional angiography, while blinded to the other imaging 
modality. The results of the primary end point based on coro-
nary anatomy alone have been recently published.6 The pres-
ent analysis focuses on a second level of the 2 heart teams 
decision-making after the incorporation of the physiology com-
ponent (FFRCT) in the coronary CTA diagnostic strategy arm, 
which represents the secondary end point of the SYNTAX III 
REVOLUTION trial.5 The study was approved by an institutional 
review committee, and the subjects gave informed consent. 
The European Cardiovascular Research Institute (Rotterdam, 
the Netherlands) with unrestricted grants from GE Healthcare 
(Chicago, IL) and Heart Flow Inc (Redwood City, CA) spon-
sored the study.
Enrolment and Randomization
Patients with left main or 3-vessel CAD diagnosed with either 
coronary CTA or conventional angiography and candidates 
AQ6
Nonstandard Abbreviations and Acronyms
CABG coronary artery bypass grafting
CAD coronary artery disease
CTA  coronary computed tomography 
angiography
FAME  Fractional Flow Reserve Versus Angiog-
raphy for Multivessel Evaluation
FFR fractional flow reserve
FFRCT  fractional flow reserve derived from 
computed tomography
PCI percutaneous coronary interventions
WHAT IS KNOWN
• The SYNTAX III Revolution trial showed that in 
patients with 3-vessel coronary artery disease 
treatment decision-making based on coronary 
computed tomography angiography is in high 
agreement with the decision derived from conven-
tional angiography.
• Physiology-guided (invasive fractional flow reserve 
[FFR]) percutaneous coronary revascularization 
has been associated with lower rate of MACE com-
pared with invasive angiographic guidance and is 
recommended by the latest guidelines.
WHAT THE STUDY ADDS
• The heart team changed the treatment recommen-
dation in 7% of the cases and modified the selec-
tion of vessels to be revascularized in 12% when 
functional evaluation with FFRCT was added to an 
anatomic assessment with coronary computed 
tomography angiography alone.
• In patients assessed by coronary computed tomog-
raphy angiography, FFRCT reduced the proportion 
of patients with hemodynamically significant 3-ves-
sel coronary artery disease from 92.3% to 78.8% 
and reclassified to a lower SYNTAX Score 15.5% 
of patients.
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for either PCI or CABG were assessed for eligibility. Patients 
were consented to undergo coronary CTA using a whole-
heart coverage, high-definition CT scanner (Revolution CT; GE 
Healthcare, Chicago, IL), and to participate in a randomized trial 
of decision-making between PCI and CABG performed by the 
local heart team and relying on alternative imaging techniques. 
Two heart teams composed by an interventional cardiologist, a 
cardiac surgeon and a radiologist specialized in cardiac imag-
ing, were randomized to either assess the coronary anatomy 
with coronary CTA or conventional angiography in addition to 
the patient’s clinical information. The heart team allocated to 
coronary CTA had to make a second treatment decision and 
procedural planning taking into consideration the functional 
component of the coronary stenoses provided by FFRCT. 
Similarly, the heart team randomized to conventional angiog-
raphy received coronary CTA with FFRCT and had to make a 
second treatment decision based on the 3 diagnostic methods. 
Each heart team calculated the anatomic SYNTAX score based 
only on their allocated imaging modality, the noninvasive func-
tional SYNTAX score, and subsequently integrated the clini-
cal information to compute the SYNTAX score III providing a 
treatment recommendation, that is, CABG, PCI, or equipoise 
between CABG and PCI. Any anatomic SYNTAX score was eli-
gible for screening, and patients with anatomic SYNTAX score 
>33 were not excluded. Patients with prior revascularization 
were excluded. Complete details of the inclusion and exclusion 
criteria have been previously described.5,6
Image Acquisition and Analysis
Coronary CTA was performed with the GE Revolution CT 
scanner.7 A proprietary post-processing algorithm (Snap Shot 
Freeze) allowed for the correction of motion artifacts.8 The 
imaging acquisition guidelines are detailed in the Table I in the 
Data Supplement. Image quality was assessed using the 5-point 
Likert scale at the patient level. The 2 local heart teams signed 
off their decision on the choice of revascularization mode based 
on the anatomic assessment alone. Subsequently, the FFRCT 
was used to calculate the noninvasive functional SYNTAX 
score, computed by subtracting nonflow limiting stenoses 
(FFRCT >0.80) from the anatomic SYNTAX score. FFRCT has 
a lower limit of detection of 0.50. Finally, the noninvasive func-
tional SYNTAX score was used to calculate the SYNTAX Score 
III, which is conceptually a combination of coronary anatomy 
complexity with its functional repercussion and patient’s clini-
cal characteristics and comorbidities. The anatomic and func-
tional SYNTAX scores were also calculated by an independent 
core laboratory (Cardialysis BV, Rotterdam, the Netherlands) 
and were made available to each heart team for consultation. 
For the present article, the functional SYNTAX score was cal-
culated from the heart team assessment, whereas lesion level 
data were analyzed by the core laboratory (Cardialysis BV, 
Rotterdam, the Netherlands).
Objectives
The primary objective of the present study was to determine 
the proportion of patients in whom FFRCT changed the treat-
ment decision and the selection of vessels for revascularization 
with respect to the management based on anatomic assess-
ment with either coronary CTA or conventional angiography. 
The secondary objective was to assess the impact of FFRCT on 
patients risk reclassification compared to the anatomic assess-
ment alone using the SYNTAX score tertiles (SYNTAX score: 
0–22, 23–32, and >32).
Statistical Analysis
The heart team’s treatment recommendation led to one of 3 
decisions according to the SYNTAX Score III: (1) CABG only, 
patients should be treated by CABG due to a higher 4-year 
mortality with PCI; (2) PCI only, patients should be treated 
by PCI due to a higher 4-year mortality with CABG; and (3) 
equipoise between CABG and PCI, patients could be treated 
by either approach, considering that the 4-year mortality pre-
diction is similar between them. The power calculation of the 
sample size of the SYNTAX III REVOLUTION Trial has been 
previously described.5 The risk reclassification is presented as 
the proportion of patients reclassified from the anatomic to 
the functional SYNTAX score tertiles (ie, low <22, intermedi-
ate 23–32, and high >32). Comparison of the continuous ana-
tomic SYNTAX scores was performed with the paired t test. 
Differences in categorical variables were assessed with the use 
of McNemar test, since they were from a matched population. 
Agreement between (1) SYNTAX II recommendation strategies 
derived from angiography only versus that derived from angiog-
raphy with CTA and FFRCT and between (2) tertiles of anatomic 
SYNTAX score derived from different imaging strategies were 
assessed with the concordance coefficient of κ. A 2-sided P 
value of 0.05 or less was considered to indicate statistical sig-
nificance. All statistical analyses were performed with the use 
of SAS software, version 9.4 (SAS Institute).
RESULTS
From June 29, 2016 to February 8, 2018, 223 patients 
with left main or 3-vessel CAD were enrolled in 6 centers 
from 5 European countries. Baseline clinical characteris-
tics and CT acquisition information are shown in Table II 
in the Data Supplement. Coronary CTA assessment was 
feasible in 99% of the patients, and the FFRCT analysis 
was available in 196 patients (88% of the entire study 
population; Figure 1). FFRCT was available for 1030 
lesions and was positive (≤0.80) in 89% of them (mean 
FFRCT value 0.64±13; Figure 2).
Impact of FFRCT on the Treatment Decision 
Based on Coronary CTA
Using coronary CTA alone, 1108 stenoses (5.0±1.7 
per patient) were detected. The mean anatomic SYN-
TAX score derived from coronary CTA was 33.9±13.0 
(n=233 patients). The heart teams subtracted 205 
lesions, assessed as nonfunctionally significant, for 
the functional SYNTAX score calculation. This led to a 
reduction of the noninvasive functional SYNTAX score 
(n=196) to 30.5±13.0 (P value <0.001 versus anatomic 
SYNTAX score). The inclusion of the physiology compo-
nent led to a mean reduction of the SYNTAX score of 
3.7 points. Table 1 shows the impact of the physiology 
information on the SYNTAX score components.
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Based on the functional SYNTAX score according to 
FFRCT, SYNTAX score III recommended CABG only in 
24% (47/194) of the patients and the heart team treat-
ment decision was CABG in 69% (161/194) of the 
cases. FFRCT changed the treatment decision between 
CABG and PCI in 7% (14/194) of the patients and 
modified the revascularization strategy in 12.1% of the 
vessels. Compared with anatomic coronary CTA assess-
ment, addition of FFRCT reduced the number of patients 
with significant 3-vessel CAD from 92.3% to 78.8%.
Impact of Coronary CTA With FFRCT on 
Treatment Decision Based on Conventional 
Angiography
Conventional coronary angiography identified 1073 ste-
noses (4.8±1.7 per patient) with a mean SYNTAX score 
of 30.3±12.2. Further evaluation with coronary CTA and 
FFRCT removed 129 nonhemodynamically significant 
lesions from the functional SYNTAX score calculation; 
however, the mean SYNTAX score remained unchanged 
(31.2±13.4; Table 2). The SYNTAX score III recom-
mended CABG only in 26% (50/196) of the patients, 
and CABG was selected as the treatment by the heart 
team in 69% (135/196) of the patients. The addition 
of FFRCT changed the heart team’s treatment selection 
in 6.6% of patients and modified treatment planning in 
18.3%. The number of patients with significant 3-vessel 
CAD remained unchanged (86.1% versus 86.2%).
Risk Reclassification
Using FFRCT, 15.5% (30/194) of the patients were 
reclassified to a lower risk SYNTAX score tertile based 
on coronary CTA alone (Table III in the Data Supplement, 
Figure 3A). Similarly, the addition of noninvasive func-
tional assessment to conventional angiography reclassi-
fied 14% (31/221) of the patients to a lower risk tertile 
T2
F3
Figure 1. Revolution SYNTAX III 
Study flow chart.  
FFRCT indicates fractional flow reserve 
derived from computed tomography 
angiography.
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(Table IV in the Data Supplement, Figure 3B). The rec-
ommendation based on the SYNTAX II score changed 
in 6.7% of the patients (ie, in 3.1% of the patients, the 
recommendation changed from CABG only to equipoise 
by adding FFRCT to conventional angiography, and in 
3.6% the recommendation changed from equipoise to 
CABG only). The agreement was high with a κ of 0.82 
(0.73–0.92; Table 3).
DISCUSSION
The main findings of the present study can be summa-
rized as follows: (1) by including the noninvasive func-
tional evaluation with FFRCT, the heart team changed 
the treatment recommendation in 7% of the cases and 
modified the selection of vessels for revascularization 
in 12% as compared with a coronary CTA assessment 
alone. Moreover, inclusion of FFRCT information on top of 
conventional angiography changed the treatment recom-
mendation in 6.6% of the cases and modified the plan-
ning in 18.3%; (2) the noninvasive functional SYNTAX 
score reclassified 15.5% of the patients to a lower SYN-
TAX score tertile based on coronary CTA and 14% of the 
patients to a lower SYNTAX score tertile based on con-
ventional angiography; and (3) in patients assessed by 
coronary CTA, FFRCT reduced the proportion of patients 
with hemodynamically significant 3-vessel CAD from 
92.3% to 78.8%.
It is noteworthy that in this study anatomically nonsig-
nificant lesions were not scored in the calculation of the 
coronary CTA SYNTAX score, even if the FFRCT in the 
distal vessel was positive. On the contrary, when FFRCT 
was ≤0.8 in the proximal coronary segments, all distal 
lesions were considered significant. This approach might 
underestimate the clinical impact of FFRCT, and technical 
improvements are ongoing to overcome the limitation.
Use of physiology-guided percutaneous revascular-
ization has shown to reduce the rate of major adverse 
cardiovascular events compared with angiographic guid-
ance alone and has been recommended by the latest 
guidelines to identify hemodynamically relevant lesions.9 
In the SYNTAX II study, which included patients with 
3-vessel disease without left main involvement and 
moderate anatomic complexity (mean SYNTAX score 
20.3±6.4), routine physicological assessment (per-
formed in 82.8% of patients) reduced the percentage 
of patients with 3-vessel disease to 37.2%.10 At vari-
ance with SYNTAX II, the SYNTAX III REVOLUTION trial 
included patients with more severe CAD, as underlined by 
a mean anatomic SYNTAX score of 30.0±12.0.6 More-
over, the proportion of lesions with a positive FFR was 
89% in SYNTAX III and 74.6% in SYNTAX II. In SYNTAX 
II, inclusion of FFRCT reclassified 30% of the patients to 
a lower SYNTAX score tertile, which is a higher propor-
tion than that observed in the present study. The limited 
exclusion criteria of SYNTAX III, particularly the inclusion 
of patients with left main coronary artery stenosis, are 
likely responsible for this finding and underline the func-
tional compromise of unselected patients with multives-
sel CAD. Of note, 11% of the coronary lesions in this 
complex population were found to have a value higher 
than 0.80 at FFRCT, and this finding influenced the treat-
ment decision in 6% of the patients and modified treat-
ment planning in 16%.
In a large, retrospective study, FFR-guided CABG 
is associated with a reduction in death and myocardial 
infarction compared with angiography-guided CABG at 
6-year follow-up.11 We may expect an increase in func-
tional-guided CABG in the upcoming years. In particular, 
coronary CTA with FFRCT may provide to interventional 
cardiologists and cardiac surgeons a combined anatomic 
and functional noninvasive assessment of multivessel 
disease for the type and modality of revascularization. 
Indeed, one of the potential advantages of FFRCT is the 
possibility to interrogate the physiology of any segment 
in the epicardial coronary circulation.12–14 From the heart 
T3
Figure 2. Flow reserve derived from 
computed tomography angiography 
(FFRCT) values distribution.  
The diagram shows the number of lesions 
divided into incremental FFRCT values. 
*Because the lower limit of detection of 
FFRCT is 0.5, values presented at this 
interval 0.50–0.525 also represent all 
values below 0.5.
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team’s perspective, a nonhemodynamically significant 
lesion in the left anterior descending artery may prompt 
a change in the treatment strategy, favoring a percuta-
neous interventional approach in a multivessel disease 
patient. Moreover, in patients undergoing CABG, the 
recognition of nonhemodynamically significant lesions 
may reduce unnecessary grafts, surgical time, and might 
result in higher graft patency. The ongoing FAME 3 Trial 
(Fractional Flow Reserve Versus Angiography for Multi-
vessel Evaluation), a comparison of FFR-guided PCI and 
CABG surgery in patients with multivessel CAD, will pro-
vide further clinical evidence of the potential benefit of 
FFR-guided surgical revascularization.15
Practical implementation of pressure-wire assess-
ment of coronary lesions is still low worldwide. Further-
more, multivessel FFR or instantaneous wave-free ratio 
evaluation is seldom performed before a revasculariza-
tion procedure, particularly before CABG. FFRCT has the 
potential to refine the heart team’s treatment decision 
and planning by incorporating the functional component 
of coronary epicardial lesions. The results of the present 
study support the feasibility and utility of preprocedural 
physiology assessment to better select and guide the 
Table 2. Anatomy and Functional SYNTAX Score 
Assessment in The Heart Team Randomized to 
Conventional Angiography
Characteristics
Conventional Angiography First Strategy
P Value
Conventional 
Angiography Only 
223 Patients
Conventional 
Angiography and 
Coronary CTA With 
FFRCT 196 Patients
Number of lesions 1073 944  
Diseased vessels
 RCA 92.4% (206/223) 93.9% (184/196) 1.0
 LAD 96.4% (215/223) 97.4% (191/196) 0.63
 LCX 95.1% (212/223) 92.3% (181/196) 0.15
 Left main diseased 28.7% (64/223) 28.1% (55/196) 1.0
Anatomy and functional SYNTAX score components:
 Total occlusion 14.0% (150/1073) 13.6% (128/944) 0.42
 Trifurcation 2.4% (26/1073) 2.2% (21/944) 1.0
 Bifurcation 22.0% (236/1073) 21.3% (201/944) 0.88
Type of bifurcation
  Medina 1,0,0 1.7% (18/1073) 1.2% (11/944) 0.07
  Medina 0,1,0 2.6% (28/1073) 1.8% (17/944) 0.33
  Medina 1,1,0 4.4% (47/1073) 5.0% (47/944) 0.28
  Medina 1,1,1 6.8% (73/1073) 7.2% (68/944) 0.66
  Medina 0,0,1 2.4% (26/1073) 1.5% (14/944) 0.21
  Medina 1,0,1 2.2% (24/1073) 2.8% (26/944) 0.23
  Medina 0,1,1 1.9% (20/1073) 1.9% (18/944) 0.84
 Aorto-ostial lesion 3.3% (35/1073) 3.7% (35/944) 0.86
 Severe tortuosity 2.2% (24/1073) 0.8% (8/944) 0.002
 Length >20 mm 29.1% (269/923) 30.1% (246/816) 0.15
 Heavy calcification 13.0% (140/1073) 20.9% (197/944) <0.001
 Thrombus 0.3% (3/1073) 0.6% (6/944) 0.125
  Anatomy and 
functional SYNTAX 
score
30.3±12.2 31.2±13.4  
  1-vessel disease 1.3% (3/223) 1.5% (3/196) 1.0
  2-vessel disease 12.1% (27/223) 11.7% (23/196) 1.0
  3-vessel disease 86.1% (192/223) 86.2% (169/196) 0.82
 Left main only 0.4% (1/223) 0.5% (1/196) 1.0
 3-vessel disease 
(or 3-VD equivalent)
86.5% (192/222) 86.7% (169/195) 0.82
McNemar test used to compare matched categorical variables. CTA indicates 
computed tomography angiography; FFRCT, fractional flow reserve derived from 
computed tomography angiography; LAD, left anterior artery; LCX, left circumflex; 
and RCA, right coronary artery.
Table 1. Anatomy and Functional SYNTAX Score 
Assessment in the Heart Team Randomized to Coronary CTA
Characteristics
Coronary CTA Only 
223 Patients
Coronary CTA With 
FFRCT 194 Patients P Value
Number of lesions 1108 903  
Diseased vessels
 RCA 95.5% (212/222) 86.6% (168/194) <0.001
 LAD 99.5% (221/222) 96.9% (188/194) 0.063
 LCX 95.0% (211/222) 90.7% (176/194) 0.039
 Left main 36.0% (80/222) 30.4% (59/194) 0.006
Anatomy and functional SYNTAX score components
 Total occlusion 12.0% (133/1108) 12.8% (116/903) 0.5
 Trifurcation 2.2% (24/1108) 1.6% (14/903) 1.0
 Bifurcation 23.4% (259/1108) 22.5% (203/903) 1.0
 Type of bifurcation
  Medina 1,0,0 1.1% (12/1108) 1.1% (10/903) 1.0
  Medina 0,1,0 0.8% (9/1108) 0.9% (8/903) 1.0
  Medina 1,1,0 6.9% (77/1108) 6.9% (62/903) 1.0
  Medina 1,1,1 8.6% (95/1108) 8.4% (76/903) 1.0
  Medina 0,0,1 1.8% (20/1108) 1.6% (14/903) 1.0
  Medina 1,0,1 1.9% (21/1108) 1.8% (16/903) 1.0
  Medina 0,1,1 2.3% (25/1108) 1.9% (17/903) 1.0
 Aorto-ostial lesion 3.6% (40/1108) 3.0% (27/903) 0.13
 Severe tortuosity 0.9% (10/1108) 1.1% (10/903) 1.0
 Length >20 mm 30.4% (296/975) 30.0% (236/787) 0.25
 Heavy calcification 28.9% (320/1108) 27.1% (245/903) 1.0
 Thrombus 0.3% (3/1108) 0.3% (3/903) 1.0
  Anatomy and 
functional SYNTAX 
score
33.9±13.0 30.5±13.0  
   1-vessel disease 0.9% (2/222) 3.1% (6/194) 0.22
  2-vessel disease 6.8% (15/222) 18.0% (35/194) <0.001
  3-vessel disease 91.9% (204/222) 78.4% (152/194) <0.001
 Left main only 0.5% (1/222) 0.5% (1/194) 1.0
 3-vessel disease (or 
3-VD equivalent)
92.3% (204/221) 78.8% (152/193) <0.001
McNemar test used to compare matched categorical variables. CTA indicates 
computed tomography angiography; FFRCT, fractional flow reserve derived from 
computed tomography angiography; LAD, left anterior artery; LCX, left circumflex; 
and RCA, right coronary artery.
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revascularization strategy in patients with multivessel 
CAD. Moreover, the high accuracy of FFRCT in patients 
with multivessel disease and the safety regarding radia-
tion dose achievable with the latest generation scan-
ners16 make the noninvasive physiology assessment a 
very promising tool for the evaluation of patients with 
multivessel disease before a revascularization proce-
dure. Progress in the field of coronary CTA, FFRCT, and 
the application of machine learning on fluid dynamic 
analysis have proven to be clinically relevant.17 Of note, 
the acceptance rate for FFRCT analysis in the present 
study was very high (88%), particularly if compared with 
that reported in other prospective multicenter trials. For 
example, it was 33% in the PROMISE trial18 and 69% in 
the SYNTAX II.4 However, the high rate of coronary CTA 
suitability for FFRCT appears not surprising if we consider 
the scanner used in the SYNTAX III trial that combines 
fast gantry rotation time and intracycle motion-correction 
algorithm aimed at reducing the impact of motion arti-
facts on image quality.19
Future Perspectives
The present study opens new perspectives on the use 
of coronary CTA as a tool to provide the interventionalist 
and cardiac surgeon with an anatomy and functional non-
invasive road-map for myocardial revascularization strat-
egy. Moreover, full automation of the SYNTAX III score 
has the potential to further enhance the decision-making 
process in patients with multivessel disease. The interac-
tive planner, which is a new application of FFRCT, could 
improve treatment selection while tailoring procedural 
planning based on assessing functional outcomes after 
virtual treatment.20 In this novel and growing clinical field, 
stress myocardial CT perfusion has been introduced as a 
new tool for evaluating the functional relevance of coro-
nary stenoses.21–25 However, unlike FFRCT, CT perfusion 
requires an additional scan, use of a stressor agent, and 
is associated with higher radiation exposure.26 Moreover, 
use of an adenosine-stress protocol may raise some 
safety concerns particularly in patients with left main or 
3-vessel CAD.
Limitations
Some limitations of this study should be acknowledged. 
First, due to the study design, no data on the diagnostic 
accuracy of FFRCT versus invasive FFR were assessed. 
However, physiological evaluation with FFRCT has been 
shown to be accurate in multivessel CAD patients.4 Sec-
ond, SYNTAX III Revolution was a decision-making trial; 
Figure 3. Flow reserve derived from computed tomography angiography (FFRCT) and risk reclassification.  
The figure shows the impact of the noninvasive functional SYNTAX score on risk reclassification of patients assessed by coronary computed 
tomography angiography (CTA; A) and ICA (B). The red, green, and blue squares show the proportion of patients in whom the 2 imaging 
techniques are concordant in SYNTAX risk classification, respectively.
AQ7
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Table 3. Level of Agreement Between Conventional 
Angiography Only vs Coronary CTA and Conventional 
Angiography With Functional Assessment by FFRCT
Recommendation 
Based on 
Angiography Only
Recommendation Based on Angiography and 
Coronary CTA With FFRCT
CABG Only PCI Only/Equipoise
CABG only 21.9% (43/196) 3.1% (6/196)
PCI only/equipoise 3.6% (7/196) 71.4% (140/196)
 Number %, 95% CI κ, 95% CI
Concordance 183 93.4 (88.9–96.4) 0.82 (0.73–0.92)
Recommendation are based on SYNTAX II Score. CABG indicates coronary 
artery bypass grafting; CTA, computed tomography angiography; FFRCT, fractional 
flow reserve derived from computed tomography angiography; and PCI, 
percutaneous coronary interventions.
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thus, the clinical application of FFRCT derived SYNTAX III 
score requires further investigation in a clinical outcome 
trial. Third, we recognize that this study was not designed 
to indicate to what degree FFRCT may influence patients 
management.
Conclusions
In patients with left main or 3-vessel CAD, a noninva-
sive physiology assessment using FFRCT changed heart 
team’s treatment decision-making and selection of ves-
sels for revascularization in one-fifth of the patients. This 
may improve the appropriateness and clinical outcome of 
myocardial revascularization treatment.
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